Impact of beta blockers on patients undergoing transcatheter aortic valve replacement: the OCEAN-TAVI registry.
Tetsuya SaitoNobuhiro YoshijimaHiromu HaseFumiaki YashimaHikaru TsurutaHideyuki ShimizuKeiichi FukudaToru NaganumaKazuki MizutaniMotoharu ArakiNorio TadaFutoshi YamanakaShinichi ShiraiMinoru TabataHiroshi UenoKensuke TakagiAkihiro HigashimoriYusuke WatanabeMasanori YamamotoKentaro HayashidaPublished in: Open heart (2020)
Preprocedural beta-blocker administration was not associated with 2-year cardiovascular and non-cardiovascular mortality in overall, but was associated with a lower 2-year cardiovascular mortality in patients with a history of CABG, presence of PAD, BNP ≥400 pg/mL and post-LVEF <50%. The findings must be validated using randomised trials.
Keyphrases
- transcatheter aortic valve replacement
- aortic valve
- aortic stenosis
- patients undergoing
- cardiovascular events
- clinical trial
- transcatheter aortic valve implantation
- angiotensin converting enzyme
- risk factors
- open label
- ejection fraction
- coronary artery disease
- randomized controlled trial
- cardiovascular disease
- coronary artery bypass grafting
- study protocol
- angiotensin ii